Show simple item record

dc.contributor.authorSchettini, F
dc.contributor.authorSobhani, N
dc.contributor.authorIanza, A
dc.contributor.authorTriulzi, T
dc.contributor.authorMolteni, A
dc.contributor.authorLazzari, MC
dc.contributor.authorStrina, C
dc.contributor.authorMilani, M
dc.contributor.authorCorona, SP
dc.contributor.authorSirico, M
dc.contributor.authorBernocchi, O
dc.contributor.authorGiudici, F
dc.contributor.authorCappelletti, MR
dc.contributor.authorCiruelos, E
dc.contributor.authorJerusalem, G
dc.contributor.authorLoi, S
dc.contributor.authorFox, SB
dc.contributor.authorGenerali, D
dc.date.accessioned2020-11-17T03:32:07Z
dc.date.available2020-11-17T03:32:07Z
dc.date.issued2020-08-07
dc.identifierpii: 10.1007/s10549-020-05856-3
dc.identifier.citationSchettini, F., Sobhani, N., Ianza, A., Triulzi, T., Molteni, A., Lazzari, M. C., Strina, C., Milani, M., Corona, S. P., Sirico, M., Bernocchi, O., Giudici, F., Cappelletti, M. R., Ciruelos, E., Jerusalem, G., Loi, S., Fox, S. B. & Generali, D. (2020). Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. BREAST CANCER RESEARCH AND TREATMENT, 184 (2), pp.421-431. https://doi.org/10.1007/s10549-020-05856-3.
dc.identifier.issn0167-6806
dc.identifier.urihttp://hdl.handle.net/11343/251532
dc.description.abstractPURPOSE: mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the association between treatment-associated immune system features and everolimus activity. METHODS: We retrospectively explored a correlation with the therapeutic activity of everolimus and tumor-associated immune pathways with ingenuity pathway analysis (IPA), neutrophil-to-lymphocyte ratio (NLR), circulating lymphocytes, and endothelial cells (CECs) in 3 different HR+ mBC studies, including the BALLET phase IIIb study. RESULTS: The circulating levels of CD3+/CD8+, CD3+/CD4+, and overall T lymphocytes were higher in responders versus non-responders at baseline (p = 0.017, p < 0.001, p = 0.034) and after treatment (p = 0.01, p = 0.003, p = 0.023). Reduced CECs, a tumor neoangiogenesis marker, were observed in responders after treatment (p < 0.001). Patients with low NLR (≤ 4.4) showed a better progression-free survival compared to patients with high NLR (> 4.4) (p = 0.01). IPA showed that the majority of immunity-related genes were found upregulated in responders compared to non-responders before treatment, but not after. CONCLUSIONS: Lymphocytes subpopulations, CECs and NLR could be interesting biomarkers predictive of response to everolimus-based regimens, potentially useful in daily clinical practice to select/monitor everolimus-based treatment in mBC. Further studies to confirm such hypotheses are warranted.
dc.languageEnglish
dc.publisherSPRINGER
dc.titleImmune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
dc.typeJournal Article
dc.identifier.doi10.1007/s10549-020-05856-3
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.source.titleBreast Cancer Research and Treatment
melbourne.source.volume184
melbourne.source.issue2
melbourne.source.pages421-431
dc.rights.licenseCC BY
melbourne.elementsid1461776
melbourne.contributor.authorFox, Stephen
melbourne.contributor.authorLoi, Sherene
dc.identifier.eissn1573-7217
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record